Variability in drug efficacy and adverse effects are observed in clinical practice. While the 17 extent of genetic variability in classical pharmacokinetic genes is rather well understood, the 18 role of genetic variation in drug targets is typically less studied. Based on 60,706 human 19 exomes from the ExAC dataset, we performed an in-depth computational analysis of the 20 prevalence of functional-variants in in 806 drug-related genes, including 628 known drug 21 targets. We find that most genetic variants in these genes are very rare (f < 0.1%) and thus 22 likely not observed in clinical trials. Overall, however, four in five patients are likely to carry a 23 functional-variant in a target for commonly prescribed drugs and many of these might alter 24 drug efficacy. We further computed the likelihood of 1,236 FDA approved drugs to be affected 25 by functional-variants in their targets and show that the patient-risk varies for many drugs with 26 respect to geographic ancestry. A focused analysis of oncological drug targets indicates that the 27 probability of a patient carrying germline variants in oncological drug targets is with 44% high 28 enough to suggest that not only somatic alterations, but also germline variants carried over into 29 the tumor genome should be included in therapeutic decision-making. 30
3 About three in five Americans aged 20 and above take prescription drugs every month 1 and 31 many either encounter adverse drug reactions or reduced treatment efficacy 2 . The strong 32 genetic component of altered drug response in patients is well known 3 and attributed to variants 33 affecting drug pharmacokinetics (PK) and pharmacodynamics (PD) 4 . Methods to identify these 34 genetic determinants have been developed in population stratified [5] [6] [7] or individualized 35 settings 4,8 . Particularly, the vast amount of genetic information now available has opened up the 36 possibility to systematically study inter-individual differences in drug response using genome-37 wide association (GWA) studies 9,10 . Results of these efforts have so far led to the 38 pharmacogenomics labeling of 170 drugs by the Food and Drug Administration (FDA) 11 and 39 the establishment of pharmacogenomics screening in many large hospitals in the US 12 and 40 Europe 13 . 41
However, typical pharmacogenomics GWA studies struggle with study sizes that are only large 42 enough to detect common variants with an effect on the phenotype, but are unable to 43 statistically pick up signals from rare variants with a functional effect 9,10 . Thus, data from 44 recent genetic population catalogs such as the 1,000 Genomes project 14 and the NHLBI Exome 45
Sequencing Project (ESP) have been used to determine the spectrum of variation in 46 pharmacokinetics-related genes. While classification of common and rare varies by study, 47 especially variants considered to be on the rare end of the spectrum (minor allele frequency 48 (minor AF) < 0.5%) were found abundantly in genes associated with drug absorption, 49 distribution, metabolism, or excretion (ADME) 15, 16 as well as in potential drug targets 17 . Based 50 on these surveys, it was estimated that at least 97% of individuals carry actionable high-risk 51 pharmacological variants affecting drug ADME in their genome 12, 18 . However, the role of 52 genetic variation in pharmacologically established drug targets is less well studied. 53 4
The Exome Aggregation Consortium (ExAC) 19 has aggregated data from several large 54 sequencing studies comprising exome sequencing data of 60,706 individuals -nearly an order 55 of magnitude larger than the public population catalogs mentioned above. Using a cohort of 56 this size, it now becomes possible to study even very rare variants in drug target and ADME 57 genes and to calculate the overall risk of containing a functional-variation for each patient. 58
Furthermore, even though geographic ancestry is a known confounding factor for drug 59 response and has been incorporated in clinical decision making in the absence of individual 60 genotype data 20 , a comprehensive inventory of functional genetic variation in drug-associated 61 genes across populations is still lacking. A cohort of the size of the ExAC catalog now allows 62 determining the allele frequency of very rare variants in distinct population sub-groups and 63 comparing their prevalence. 64
In this study, we provide a comprehensive analysis of genetic variation predicted to result in 65 altered protein function ("functional-variants") in 806 drug-related genes including 628 drug 66 targets (163 targeted by cancer-therapeutics). We further describe how this may affect the 67 likelihood of 1,236 FDA approved drugs to be affected by functional-variants in their targets 68 and how this likelihood varies between different populations. 69
Results

70
Drug-related genes show high extent of genetic variability across 60K individuals 71
To explore the extent of non-synonymous genetic variation in drug-related genes in the human 72 populations, we analyzed single nucleotide variants in 60,706 human individual exomes from 73
ExAC 19 in a set of 806 drug-related genes collated from DrugBank 21 and other sources 15,22 ( Fig.  74 1a, Supplementary Table 1 ). The AF distribution of non-synonymous variants in drug-related 75 genes is almost identical to that of all genes (n=17,758) and 97.5% of observed non-76 synonymous variants have an allele frequency < 0.1% (sometimes termed a "rare variant" 19 ) 77 ( Fig. 1b, Supplementary Fig. 1 ). Of note, 71% of the variants in the human exome, including 78 drug-related genes have not been observed previously in public repositories such as dbSNP and 79 therefore can be considered novel ( Supplementary Fig. 1) . 80
To identify variants that are most likely to affect the gene function ("functional-variants"), we 81 filtered the set of non-synonymous variants for those resulting in the loss of the protein product 82
("loss-of-function", LoF) 19 , or predicted to be "damaging" by PolyPhen-2 23 and SIFT 24 . This 83 resulted in 61,134 functional-variants in 806 drug-related genes (of which 767 genes included 84 at least one LoF variant) and, not surprisingly, these functional-variants tend to have lower AFs 85 than all other non-synonymous variants (98.7% have an allele frequency < 0.1%) ( Fig. 1c) . 86
Nevertheless, 43% of the drug-related genes with predicted functional-variants have at least 87 one functional-variant with AF ≥ 0.1%. The drug-related genes with the most frequent 88 functional-variants are membrane transporter genes related to drug efflux and uptake such as 89 ABCB5 (three LoF, six damaging), SLC22A1 (nine damaging), and SLC22A14 (eight 90 damaging). In the clinically highly important polymorphic cytochrome P450 enzyme CYP2D6 91 also eight damaging variants have been identified ( Supplementary Table 2 ). Since the ExAC 92 cohort contains an order of magnitude more individuals than previously available, it also 93 allowed us to identify genes with many different functional-variants even though each variant 94 may be individually rare. The ADME genes with the most functional-variants per residue 95 reflect similar findings from smaller cohort studies and include the glutathione S-transferase 96 sodium/bile transporter SLC10A1 (0.36 variants/residue), GSTA5 (0.31 variants/residue), and 97 some cytochromes P450s such as CYP1A1 (0.30 variants/residue) and CYP2C19 (0.28 98 7 non-negligible proportion of the score is contributed by rare functional-variants, which were 122 identified through the sufficiently large cohort size (see the lines in light purple and light blue 123
in Figure 2a and 2b, respectively and Supplementary Table 2 ). In addition, we estimate that 124 more than 60% of the drug-related genes in our set are putative novel candidates for 125 pharmacogenomic research, so far missing relevant information from clinical studies 126 ( Supplementary Fig. 2 ) 27 . 127
Cancer drug target genes have many germline functional-variants. 128
Especially in cancer therapy, genetic variation in drug targets has been recognized to play a 129 crucial role for treatment success 28,29 . While some cancer drugs do not act in the tumor tissue, 130 the cancer drug's primary site of action usually is in the tumor, whose genome contains tumor-131 specific somatic variants as well as a subset of patient-specific germline variants 30 . Information 132 on somatic variants from tumor samples is thus increasingly used to enable research on drug 133 design and to implement stratified or personalized cancer therapy. However, the patient's 134 germline genome is routinely masked in these tumor sequencing analysis protocols 28,29 135
We thus wanted to assess whether target genes of drugs used in cancer therapy contain 136 germline variants in the population that may affect the drug action and may be missed by 137 current tumor sequencing analysis protocols. More than 15% of the drugs in this report (193 of 138 the 1,236) are used in oncology (as defined by the WHO ATC code 31 ) and between them have 139 163 gene targets. Several of these targets have high probabilities of having a functional-variant 140 in the germline ( Supplementary Table 2 ). For some of these targets the germline risk directly 141 corresponds to potential altered treatment effects. This is the case for the kinase KDR (also 142 known as VEGFR2) (CAP=25%), which is targeted by sorafenib and sunitib to inhibit 8 vascularization of the tumor site 32 . Other drug targets for cancer therapeutics with high CAP 144 scores include MAP4 (60%) and TUBB1 (30%) that are targets of paclitaxel, MAP1A (42%) a 145 target of estramustine, CD3G (39%) a target of muromonab and PARP1(37%) a target of 146 olaparib (Fig. 2) . Overall, 40 cancer drug target genes, including 34 target genes with kinase About 70% of the FDA-approved drugs analyzed here do not have any pharmacogenomics data 158 associated with them in public repositories 27 . However, our analysis shows that there are many 159 functional-variants in their target genes ( Fig. 3a ). To estimate how much each drug can be 160 affected by functional-variants in its target genes and to highlight possible candidates for future 161 research, we computed the probability of containing a functional-variant in any number of its 162 reported targets in DrugBank 21 by combining the CAP scores of the drug's target genes to a 163 "drug risk probability" (short DRP, see Methods for details). For all FDA-approved drugs 164 considered here (n=1,236), 43% have a DRP greater than 1% (Supplementary Table 4 ). The 165
DRPs are weakly correlated to the number of targets (linear regression, r 2 = 0.28), leaving 166 many drugs with few targets but higher than expected DRPs (determined by root mean square 167 errors, short RMSE, of the model, red circles in Supplementary Fig. 3 ). For instance, one of the 168 two human targets of azelaic acid, tyrosinase (TYR) is highly mutated in the population causing 169 a DRP of 62.5% for this drug, which results in an RMSE of 0.34. 170
Drugs with the top DRP scores are paclitaxel and docetaxel (82%), quinacrine (70%), azelaic 171 acid (63%), triazolam and other benzodiazepines (>50%) ( Supplementary Table 4 ). This means 172 that any individual in the population has a probability of more than 50% to carry a functional-173 variant that may affect the medication outcome of these drugs. Several of the drugs with high 174
DRPs are considered "essential medicines" by the WHO 33 . In addition to paclitaxel and 175 docetaxel, these include the opioid methadone (13.6%), the diuretic amiloride (11.7%), and the 176 local anesthetic lidocaine (11.4%). For instance, the drug methadone targets the D-and M-type 177 opioid receptors (OPRD1, OPRM1) and whilst some non-coding variants and a single coding 178 variant (rs1799971) have previously been associated with required dose adjustments and 179 treatment response, we observe another 132 functional-variants in these target genes, which 180 could therefore be candidates for further testing. Since variants with predicted damaging effects 181 dominate especially the rather high DRPs, we filtered the variants for only those resulting in 182
LoF. Restricting to these high confidence variants, the DRP decreases below 10% and the drugs 183 with the highest DRP include the anti-cancer drug marimastat (8.3%), the anti-ulcer medication 184 sulfacrate (8.2%), the anti-flu drug oseltamivir (6.0%) which targets human CES1 for 185 activation, and several liptins used for diabetes that inhibit DPP4 (5.6%) (Supplementary Table  186 4). 187
We then focused our analysis on the top 100 most prescribed medications in the US (from 188 2013 34 ) which results in a list of 77 unique drug compounds for further investigation. 42% of 189 these drugs have a DRP score greater than 1% of containing a functional-variant and the 190 probability of an individual carrying a functional-variant in any of the targets for these 77 top 191 prescribed drugs is 81%. For some of these drugs it is already well established that there is Overall, the genetic-variability of drug targets of many of the top 100 prescribed drugs has not 205 been systematically annotated so far ( Supplementary Fig. 4 ), including the Alzheimer's drug 206 memantine (DRP=7.2%), the pain-medication acetaminophen (DRP=4.7%) and the proton-207 pump inhibitor esomeprazole (DRP=3.1%) that all have high DRPs. While these drugs, to our 208 knowledge, do not have known associations between functional-variants in drug targets with 209 drug action, clinical studies show that certain proportions of patients treated with them do not 210 respond to treatment. The extent of this non-response is reflected by the number needed to 211 treat, NNT 37 . For instance, for every one patient successfully treated for Alzheimer's diseases 212 with memantine, between two and seven patients do not respond to treatment 38 (NNT=3 to 8). 213
Similarly, the NNT for acetaminophen and its indication of pain is five 39 and for esomeprazole 214 and reflux disease is 54 40 . 215
Drug-related genes show geographic difference in genetic variability. 216
It is known that individuals with different geographic ancestry carry genetic variants with 217 For instance, using a cutoff of CAP>1%, we found that 231 drug-related genes have functional 224 variants in the cohort of European ancestry compared to 298 genes with functional variants for 225 the cohort of African ancestry. 226
Nevertheless, 114 drug-related genes showed a CAP score above 1% in each population 227
indicating that there are genes with a similar world-wide pharmacogenetic relevance. 228
Not surprisingly, amongst those genes with the highest difference in CAP score between 229 populations are many cytochrome P450s and phase II enzymes ( Supplementary Table 5 ), as 230 noted in previous studies of smaller population sizes 22 . Similarly, we observe drug target genes 231 with markedly different CAP scores across populations. Among the target genes with the 232 highest absolute CAP score difference are VWF (which is targeted by antihemophilic factor), 233 SIRT5 (targeted by suramin for treating sleeping sickness), and the gastric lipase LIPF (targeted 234 by orlistat for obesity treatment). The latter has 65 functional-variants and the most frequent 235 variants differ especially between African and East Asian cohorts (CAP 8% vs 51%). Target 236 genes with high subpopulation differences also include several targets for antineoplastic agents, 237 such as the olaparib-target PARP1, for which the CAP score ranges from 10.2% in patients of 238
African ancestry to 69.6% in Latino patients. While the efficacy of olaparib depends on the 239 tumor genome and not the germline, the risk to carry germline-originated variants in the tumor 240
should not be ignored. We also observed population differences in the nucleoside transporter 241 SLC28A1. While the CAP score is 4% in Non-Finish Europeans, individuals with an East Asian 242 ancestry have a risk of 60%. Interestingly, several variants in SLC28A1 have been associated 243 with different outcomes in non-small cell lung cancer and breast cancer 42,43 when treated with 244 gemcitabine, suggesting that variant differences across the populations may be involved. 245
Analysis of the DRP score reveals a population-specific risk for several drugs 246
Of the 1,236 FDA approved drugs considered, 241 have more than 10% absolute difference in 247 DRP scores between at least two sub-population cohorts and 24 of these have more than 30% 248 DRP difference (Supplementary Table 6 ). Out of this subset of drugs, 11 belong to the 100 249 most prescribed drugs in the US and 28 are recommended worldwide by the WHO for their 250 therapeutic use, including oxcarbazepine, amobarbital and dolasetron. 312 of the 1,236 drugs 251 have a high risk (DRP>1%) in all six sub-populations ( Fig. 4A , and the DRP top 20 drugs 252 stratified by population are illustrated in Fig. 4B) . 253
Well-known differences, such as response to disulfiram (treatment for chronic alcoholism), are 254 recapitulated in the data ( Fig 4B) . Specifically, the genetic variant E487K in the disulfiram 255 target ALDH2 (rs671) is seen in the ExAC East Asian population at similarly high frequencies 256
as seen in previous genetic studies 44 . 257
13
The different responses in the asthma-medication salbutamol and the blood-thinner warfarin 258 have been attributed to variants in their respective drug targets, including R16G in ADRB2 259 (rs1042713) for salbutamol 45 and 1639G>A (rs9923231) in VKORC1 for warfarin 46 . Since the 260 well-known response altering variants were not annotated by mutation prediction software as 261 functional-variants, we did not expect to see the drugs appear high in our ranked list of risk 262 differences across the populations (see discussion). Nevertheless, our analysis shows that 263 salbutamol still has a high risk ratio between populations, caused by 29 variants with a 264 dominant contribution from one variant separating the individuals of Finnish ancestry from 265
African ancestry (rs201257377, N69S, AF FIN =0.01). To our knowledge this variant has not 266 been functionally characterized or previously associated with salbutamol response. Similarly, 267
we observe 19 functional-variants in the warfarin target VKORC1 that are population-specific, Using a recent protein 3D model 48,49 of VKORC1, we mapped the R53S variant to the putative 274 warfarin binding pocket (Fig. 3B ). Furthermore, analysis of coevolution in the protein using 275
EVfold 50 shows that R53 is strongly coupled to other residues in the protein and changes in this 276 site are predicted by EVmutation 51 to affect protein fitness due to epistatic variant effects 277 ( Supplementary Fig. 5 ). Together, this suggests that this mutation might be negatively 278 associated to warfarin binding. 279
Triflusal, a treatment for stroke re-occurrence, targets four genes (PTGS1 (also known as Cox-280 1), NOS2, NFKB1, and PDE10A) that together have more functional-variants in the African 281 population than in any other population (DRP AFR =37%, Fig. 4B ). This difference between 282 populations is mainly due to a SNP in NOS2, which occurs in the population of African 283 ancestry with higher than average frequency (rs3730017, AF AFR =19% vs AF global =4%) and 284 while not functionally characterized, has been associated with protection against cerebral 285 malaria 52 . In PTGS1, three functional-variants have allele frequencies above 0.1% in the cohort 286 of African ancestry. The most frequent variant (rs5789, L237M, AF AFR =0.5% vs 287 AF global =1.7%) lies on the dimer interface and has previously been associated with reduced 288 metabolic activity of the enzyme 53 . A second variant is an indel, which is predicted to result in 289 the total loss of protein function (AF AFR =0.3% vs AF global =0.02%). The effects of the third 290 functional-variant common in the African cohort (rs139956360, E259A, AF AFR =0.2% vs 291 AF global =0.02%) on enzyme activity or drug binding is less clear from the three-dimensional 292 structure of the protein and would require further exploration. Since triflusal is prescribed for 293 prophylactic use in the same way as aspirin for stroke prevention, it is clearly worth further 294 investigating the effects of these observed functional-variants. 295
Population differences in functional-variants for cancer drugs. 296
Our results also highlight a large DRP variability of cancer drugs between the populations. 297
While for many of these drugs not the germline but the tumor genome are relevant for drug 298 action, germline DRPs of these drugs give an estimate of the population risk to possess 299 potentially resistance-causing variants in the tumor and should be screened accordingly. For 300 instance, the DRPs of taxanes (docetaxel, paclitaxel and cabazitaxel) are 30 percentage points 301 higher in the cohorts of South Asian and European ancestry compared to the cohort of African 302 ancestry (DRP SAS/NFE =85% vs DRP AFR =45%) due to functional-variants in the four taxane 303 targets, TUBB1, MAP2, MAP4 and MAPT. Among these are three distinct positions in TUBB1 304 (Q43P/H, R307C, R359W) that occur with comparably high frequencies in the South-Asian 305 population. While Q43P (AF SAS =14%) has recently been associated with decreased 306 progression-free survival in urothelial cell carcinoma when treated with cabazitaxel 54 , less is 307 known about the effects of the other two variants. Mapping the affected residues onto the three 308 dimensional structure of docetaxel bound to tubulin (PDB ID: 1tub 55 ) shows that R359 interacts 309 with the drug (Fig. 3C ). The effect of R307C is less obvious from structural observations as it 310
does not lie very close to the binding site or the interface between the monomers in the polymer 311 (R307 to K124 < 15 Å, mapped on PDB ID: 3j6g 56 ). 312
Discussion
313
In this study, we analyzed the extent of functional genetic variation in drug-related genes and 314 its implication for 1236 FDA-approved drugs in exome sequencing data of 60,706 individuals. 315
We show that not only the risk of carrying functional-variants in ADME-related genes, but also 316 in drug targets is high for an individual patient. For ADME-genes this observation is in line 317 with previous studies 12,15,18 , but novel for drug-target genes. We observed functional-variants in 318 98% of the drug-related genes and at least one high confidence LoF variant in 93% of the 319 genes. The prevalence of functional-variants in drug-related genes is thus higher than 320 previously shown 18 . When considering drug target genes for the 100 most prescribed 321 medications in the US the probability of carrying at least one functional-variant is above 80% 322 for each patient. Together with the high risk for clinically actionable variants in ADME genes 323 (98% 12 ) these findings indicate that genetic variability may contribute significantly to observed 324 differences in drug response between patients. 325
While individualized cancer therapies often focus on the somatic variants present only in tumor 326 tissue, we can show that functional germline variants, which are routinely masked out in the 327 analysis of somatic variants, are common in many cancer drug targets. By excluding germline 328 variants that the tumor inherited from its progenitor cell from cancer genome analysis in the 329 Furthermore, to quantify the real risk for a drug, drug-specific ADME-gene relations should be 357 incorporated into the DRP calculation. For example, optimal warfarin dosing is known to be 358 dependent on variants in CYP2C9 in addition to VKORC1 60 and variants in the ADME-gene 359 UGT1A1 are documented to contribute to different responses to the cancer drug irinotecan 360 around the globe 61 . Unfortunately, comprehensive inclusion of ADME-genes in the DRP 361 calculations is currently not possible because sufficient data for ADME-genes is lacking for 362 most FDA approved drugs including the relative contribution of each enzyme. Our DRP 363 estimates thus probably still underestimate the drug-specific risk of functional variation as well 364 as population differences. 365
The vast majority of variants in drug-related genes considered in this study has not been seen 366 previously and thus lacks validated knowledge about their functional impact on drug efficacy. 367
We therefore had to rely on predictions of their impact on protein function. The probabilities 368 presented are based on the assumption that the functional classification is correct and represents 369 enzyme activity or drug efficacy. The relative risk between genes is based on the assumption 370 that there has not been a significant bias in assessment when genes already have known 371 deleterious mutations. That these assumptions are not always correct, follows from the fact that 372 variant classification tools are not exact, are often trained on disease-causing variant sets only, 373
have issues with circularity in the classifier training data, and fail to sub-classify mutations 62 . 374
Especially the distinction of activating and deactivating effects could be crucial for the 375 downstream effects on therapy. 376
This discrepancy between observed and predicted functional-effects can be illustrated on the 377 well-studied PGx variants in the anti-asthmatics target ADRB2 (R16G/rs1042713, 378 Q27E/rs1042714 and T164I/rs1800888) that all are classified as benign 45,63 . To alleviate this 379 problem, one could include additional prediction algorithms, which comes at the risk of 380 reduced specificity (in some cases more than half of all non-synonymous variants were 381 classified as functional 15 ) as all currently available methods have their individual drawbacks 64 . 382
Reliable computational classification methods for variant effects on drug response remain 383 scarce due to insufficient training data 64 , but may arise in the future if efforts are increased to 384 create such data, for example using novel high throughput methods such as deep mutational 385 scans 65,66 . For the present study we chose a conservative approach to variant annotation that 386 requires the complete loss of the protein product -which should have a marked impact on the 387 drug -or the consensus prediction of two independent prediction tools at the expense of 388 missing some known variants (Fig. 3A) . It is thus not unlikely that the effect of the functional-389 variants is still underestimated in our study. 390 Sequencing data. The use of whole exome sequencing data comes with the intrinsic limitation 391 that only variants in protein coding regions can be detected, potentially missing 392 pharmacologically relevant non-coding variants 67 or larger structural changes of the genome. 393
Furthermore, even at low false-positive rates many called variants can be inaccurate 68 Furthermore, the ExAC cohort is very large in total, but not all populations are represented 401 equally 19 . The power to detect very rare variants thus differs by an order of magnitude between 402 the individual populations (from 0.01% AF for the Finnish and East Asian populations to 403 0.001% for Non-Finnish European). Due to legal restrictions in the underlying exome 404 sequencing projects, sample-specific data including haplotype phase is missing also in ExAC. 405
Epistatic effects of variants could thus not be investigated, even though they are known to exist. 406
For example, while the single variant rs12248560 (CYP2C18*17) results in increased 407 CYP2C19 activity, the combination with another variant (rs28399504) is associated with loss-408 of-function of the protein (CYP2C19*4B) 15 . 409 Implications. Many major medical institutions have started implementing genotyping 410 protocols for preemptive pharmacogenetic testing 71-73 . However, these usually focus on a small 411 number of ADME-genes 12 and often only test a subset of established actionable variants using 412 microarrays 74 . While these arrays facilitate fast and cheap screening, we show here that the vast 413 20 majority of variants in drug-related genes seen in the human population is not covered. We 414 further want to motivate that the number of genes with pharmacogenomic variants should 415 systematically include genes implicated in drug mechanism even though only very few 416 examples in such genes have yet been characterized well enough to be part of a dosing 417 guideline. Furthermore, with allele frequencies below 0.1%, many functional-variants in drug-418 related genes are so rare that they cannot be observed in clinical trial cohorts, but may 419 contribute to adverse events or diffuse lack of efficacy post-marketing. In the future, this should 420 be in all phases of clinical drug development and the effects of genetic variants in genes 421 associated with PD and PK of the drug candidate should be systematically characterized. 422
In conclusion, large-scale sequencing efforts can be used to identify and quantify the extent of 423 genetic variation in genes relevant for drug action and metabolism. Identification of such 424 variants is only the first step towards better treatment decisions. Newly identified variants of 425 pharmacogenomics importance require validation and ultimately updated dosing guidelines. 426
The development of quality-controlled and patient-centered software solutions to combine 427 available knowledge of pharmacologically actionable variants with a patient's genome as well 428 as fast and accurate approaches (experimental and computational) to functionally classify novel 429 variants will thus be of high importance for a future of personalized medicine. 430
Materials and Methods
431
Data selection and handling 432
Known pharmacogenomics associations between drugs and genetic variants were retrieved 433 from PharmGKB 27 . Data about drugs and drug-related genes was collated from DrugBank 5 21 . 434
Information about drug approval status, ATC code, and details about the drug -gene 435 relationship (target, pharmacological action and action type) were extracted from the xml file 436 using python. We further obtained a list of the top 100 most prescribed drugs of 2013 from 437 drugs.com 34 and the list of WHO essential medicines by parsing the Index of the 19th WHO 438
Model List of Essential Medicines 33 . Drugs obtained from the top 100 list and WHO essential 439 medicines catalog were mapped to DrugBank compounds and those where this was not 440 possible were excluded. Relations between hyaluronic acid and human gene targets as well as 441 between dihydropyridines and skeletal CACNA1S were removed because the literature in the 442 database entry did not support the pharmacological involvement of these pairs. We further 443 removed Ethanol from the list of WHO essential medicines because it is listed as a surface 444 disinfectant and thus not dependent on the patient's cellular targets. 445
Drug target genes were extracted from the drug -gene relationships in DrugBank, by filtering 446 this set for only those relations with established pharmacological action flag and in which the 447 gene is annotated as drug target. Based on previous studies a list of pharmacologically relevant 448 cellular receptors, metabolic enzymes and nuclear receptors was obtained from to recent 449 pharmacogenomics surveys 15,22 and comprises the set of ADME-genes. 450
Genetic variant information including variant types, allele frequencies and deleterious 451
prediction scores were extracted from the ExAC VCF file (release 0.3) downloaded from the 452 ExAC FTP server 19 . Multi-allelic variants were split using vcflib breakmulti 453 (https://github.com/vcflib/vcflib) and synonymous variants were excluded. We then calculated 454 for each variant the allele frequency (AF) in the full cohort as well as in each ExAC population 455 separately by dividing the allele count (AC) by the allele number (AN). Following information 456 about ancestry were used: AFR=African, SAS=South-Asian, EAS=East-Asian, FIN=Finnish, 457
NFE=Non-Finnish Eurpean, AMR=Admixed American/Latino. We further excluded variants 458 whose loci were not observed at least once in every geographic population and in 50% of all 459 possible samples (i.e., minimal allele number of 60,706). After adding unique IDs to the 460 variants based on chromosome position, reference and alternative gene, we removed duplicates. 461
Identifier mapping, filtering and annotation was performed using the Konstanz Information 462
Miner (KNIME) workflow system 75 and the Python programming language (Python Software 463 Foundation, https://www.python.org/). 464
Variant subsets 465
To evaluate variants with functional effects in the ExAC catalog, we created a subsets of 466 variants with functional effects ("functional-variants"): 1) loss-of-function variants affecting 467 stop codons, splice sites and shifts in the reading frame as annotated by the Loss-Of-Function 468
Transcript Effect Estimator (LOFTEE) tool 76 in the ExAC VCF file, and 2) variants predicted 469
to have a damaging effect on the protein as predicted unanimously by PolyPhen-2 23 ('possibly 470 damaging' or 'probably damaging') and SIFT 24 ('deleterious') as annotated in the ExAC VCF 471 file. Functional-variants with allele frequencies above 0.5 were excluded from this set after 472 observing that there are annotation or reference genome mapping problems. For each gene we 473 calculated the fraction of common (AF >= 0.1%) and rare (AF < 0.1%) alleles. 474
Computation of cumulative probabilities for drugs and their related genes 475
To quantify the risk of an individual person in the population to carry functional-variants in a 476 particular gene, we define the "cumulative allele probability" (CAP) statistic, which captures 477 both the number of functional-variants and their allele frequencies per gene. Formally, this 478 score is the probability for an individual to carry at least one variant allele a of the observed 479 alleles A in a gene g. 480
Two types of CAP scores were calculated, one for all functional-variants in a drug-related gene 481
and one based only on LoF variants. 482
To estimate how much each drug can be affected by functional-variants in its target genes, we 483 further define the drug-specific "drug risk probability" (DRP) score by combining the CAP 484 scores for all drug target genes. Formally, the DRP score is defined as 485
Here G is the set of all target genes for drug D, as documented in DrugBank, and A g the set of 486 all variant alleles observed in gene g. 487
Correlation analysis of the DRP scores with the number of targets was performed using linear 488 regression with ordinary least squares fitting using the Python package statsmodels 77 to 489 compute the coefficient of determination r 2 . 490
Statistical Analysis of population differences 491
Population comparisons for CAP and DRP scores were performed using the absolute risk 492 difference (RD) metric. 493 = | event in group 2 − event in group 1 | The RD for a drug was calculated by subtracting the score from population with the smallest 494 DRP score from the score of the population with the highest DRP. To identify for which drugs 495 a population has above or below average risks (Fig. 4b) , we further calculated all pairwise risk 496 differences between populations from which we then computed the population-specific mean 497
RDs. 498
Detailed variant analyses in case studies 499
Protein structures for the porcine TUBB1 homologue (PDB IDs: 1tub 55 , 3j6g 56 ), ADRB2 (PDB 500 ID: 2rh1 78 ), PTGS1 (PDB ID: 3n8w 79 ) and NOS2 (PDB ID: 4nos 80 ), were obtained from the 501 Protein Data Bank. Recently published homology models for VKORC1 were downloaded from 502 the supplement of the respective publications 48,49 . Co-evolution analysis of residues was done 503 using plmc-based EVcouplings 50 and based on jackhmmer 81 alignments created with the 504 Uniprot entries of the respective protein as queries against the Uniref100 database 82 (release 505 01/2017). Alignment columns with more than 70% gaps and sequences with more than 50% 506 gaps were excluded from the model. Functional impact was predicted using EVmutation 51 and, 507 in the case of VKORC1, compared to experimental warfarin binding data 49 . Protein structures 508 were analyzed and rendered using the UCSF Chimera package from the Computer Graphics 509
Laboratory, University of California, San Francisco 83 . 510
Statistical analysis and code availability 511
Statistical analysis of the data set was performed in jupyter/IPython notebooks 84 using pandas 85 512 and other packages of the SciPy stack 86 . The code used to analyze the data set and produce the 513
figures will be made available on github. 514 25 515
